Natixis Advisors LLC Has $18.24 Million Position in Koninklijke Philips N.V. (NYSE:PHG)

Key Points

• Natixis Advisors LLC reduced its stake in Koninklijke Philips N.V. by 3.1%, selling 23,008 shares to end the quarter with 718,269 shares valued at $18.24 million.
• Institutional investors have shown increased activity in Koninklijke Philips, with notable positions raised by Northern Trust Corp (up 36.6%) and GAMMA Investing LLC (up 3,094.8%).
• Despite a strong earnings report beating consensus estimates, analysts have downgraded the stock from a "buy" to a "hold," with a current consensus rating of "Moderate Buy."

Natixis Advisors LLC decreased its stake in Koninklijke Philips N.V. (NYSE:PHG - Free Report) by 3.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 718,269 shares of the technology company's stock after selling 23,008 shares during the quarter. Natixis Advisors LLC owned approximately 0.08% of Koninklijke Philips worth $18,244,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its position in Koninklijke Philips by 107.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 129,624 shares of the technology company's stock worth $3,282,000 after buying an additional 67,289 shares in the last quarter. QRG Capital Management Inc. lifted its position in Koninklijke Philips by 11.0% in the 1st quarter. QRG Capital Management Inc. now owns 142,595 shares of the technology company's stock worth $3,622,000 after buying an additional 14,090 shares in the last quarter. Aurora Private Wealth Inc. purchased a new stake in Koninklijke Philips in the 1st quarter worth approximately $1,695,000. Quantinno Capital Management LP lifted its position in Koninklijke Philips by 71.1% in the 4th quarter. Quantinno Capital Management LP now owns 180,149 shares of the technology company's stock worth $4,561,000 after buying an additional 74,835 shares in the last quarter. Finally, Cerity Partners LLC raised its holdings in shares of Koninklijke Philips by 30.6% during the 1st quarter. Cerity Partners LLC now owns 80,767 shares of the technology company's stock valued at $2,051,000 after purchasing an additional 18,906 shares in the last quarter. Hedge funds and other institutional investors own 13.67% of the company's stock.

Koninklijke Philips Stock Performance

PHG traded up $0.25 during trading on Monday, hitting $26.71. The stock had a trading volume of 860,196 shares, compared to its average volume of 1,011,542. The firm has a market cap of $25.71 billion, a PE ratio of 140.55, a P/E/G ratio of 0.72 and a beta of 0.75. Koninklijke Philips N.V. has a 12 month low of $21.48 and a 12 month high of $32.91. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.69. The company has a 50 day simple moving average of $24.03 and a 200-day simple moving average of $24.97.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its earnings results on Tuesday, July 29th. The technology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.29 by $0.12. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. Analysts expect that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a report on Saturday. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy".

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.